Transcatheter aortic valve implantation reduces sympathetic activity and normalizes arterial spontaneous baroreflex in patients with aortic stenosis.

[1]  Janusz Wnek,et al.  2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.

[2]  M. Mack,et al.  Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. , 2012, The Journal of thoracic and cardiovascular surgery.

[3]  O. Alfieri,et al.  Guidelines on the management of valvular heart disease (version 2012). , 2012, European heart journal.

[4]  O. Alfieri,et al.  Guidelines on the management of valvular heart disease. , 2007, European heart journal.

[5]  P. Leprince,et al.  Registry of transcatheter aortic-valve implantation in high-risk patients. , 2012, The New England journal of medicine.

[6]  Gianfranco Parati,et al.  The human sympathetic nervous system: its relevance in hypertension and heart failure. , 2012, European heart journal.

[7]  M. Esler,et al.  Peripheral chemoreflex activation contributes to sympathetic baroreflex impairment in chronic heart failure , 2012, Journal of hypertension.

[8]  Cornelius Müller,et al.  Valvular Heart Disease Aortic Regurgitation Index Defines Severity of Peri-Prosthetic Regurgitation and Predicts Outcome in Patients After Transcatheter Aortic Valve Implantation , 2012 .

[9]  P. Vardas,et al.  Cardiac autonomic disturbances in patients with vasovagal syndrome: comparison between iodine-123-metaiodobenzylguanidine myocardial scintigraphy and heart rate variability. , 2012, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[10]  Pascal Vranckx,et al.  Standardized endpoint definitions for Transcatheter Aortic Valve Implantation clinical trials: a consensus report from the Valve Academic Research Consortium. , 2011, Journal of the American College of Cardiology.

[11]  S. Pocock,et al.  Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. , 2010, The New England journal of medicine.

[12]  P. Serruys,et al.  Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Research Consortium , 2010, European heart journal.

[13]  F. Despas,et al.  Limited prognostic value of cardiac metaiodobenzylguanidine in advanced heart failure. , 2010, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[14]  M. Labrunée,et al.  Excessive sympathetic activation in heart failure with chronic renal failure: role of chemoreflex activation , 2009, Journal of hypertension.

[15]  G. Gerosa,et al.  Expanding the eligibility for transcatheter aortic valve implantation the trans-subclavian retrograde approach using: the III generation CoreValve revalving system. , 2009, JACC. Cardiovascular interventions.

[16]  P. Serruys,et al.  Procedural and 30-day outcomes following transcatheter aortic valve implantation using the third generation (18 Fr) corevalve revalving system: results from the multicentre, expanded evaluation registry 1-year following CE mark approval. , 2008, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[17]  Francesco Maisano,et al.  Transcatheter valve implantation for patients with aortic stenosis: a position statement from the European association of cardio-thoracic surgery (EACTS) and the European Society of Cardiology (ESC), in collaboration with the European Association of Percutaneous Cardiovascular Interventions (EAPCI). , 2008, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[18]  H. Kasanuki,et al.  Prognostic value of 123I-metaiodobenzylguanidine in patients with various heart diseases , 2007, Annals of nuclear medicine.

[19]  Mirko Doss,et al.  Transapical Minimally Invasive Aortic Valve Implantation: Multicenter Experience , 2007, Circulation.

[20]  Lukas Altwegg,et al.  Percutaneous Transarterial Aortic Valve Replacement in Selected High-Risk Patients With Aortic Stenosis , 2007, Circulation.

[21]  J. Borer,et al.  The epidemiology of valvular heart disease: a growing public health problem. , 2006, Heart failure clinics.

[22]  G. Mancia,et al.  Neuroadrenergic and reflex abnormalities in patients with metabolic syndrome , 2005, Diabetologia.

[23]  Philippe Ravaud,et al.  A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. , 2003, European heart journal.

[24]  Assaf Bash,et al.  Percutaneous Transcatheter Implantation of an Aortic Valve Prosthesis for Calcific Aortic Stenosis: First Human Case Description , 2002, Circulation.

[25]  Bradley G Hammill,et al.  Validation of European System for Cardiac Operative Risk Evaluation (EuroSCORE) in North American cardiac surgery. , 2002, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[26]  G. Eisenhofer.  The role of neuronal and extraneuronal plasma membrane transporters in the inactivation of peripheral catecholamines. , 2001, Pharmacology & therapeutics.

[27]  S. Lemeshow,et al.  European system for cardiac operative risk evaluation (EuroSCORE). , 1999, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[28]  F. Grover,et al.  Risk stratification for cardiac valve replacement. National Cardiac Surgery Database. Database Committee of The Society of Thoracic Surgeons. , 1999, The Annals of thoracic surgery.

[29]  F. Florenzano,et al.  Heart rate variability in severe aortic stenosis. , 1999, The Journal of heart valve disease.

[30]  P. Merlet,et al.  Cardiac metaiodobenzylguanidine uptake in patients with moderate chronic heart failure: relationship with peak oxygen uptake and prognosis. , 1999, Journal of the American College of Cardiology.

[31]  M Pagani,et al.  Relationship between repeated measures of hemodynamics, muscle sympathetic nerve activity, and their spectral oscillations. , 1997, Circulation.

[32]  M. Ishii,et al.  Percutaneous transluminal mitral valvuloplasty normalizes baroreflex sensitivity and sympathetic activity in patients with mitral stenosis. , 1997, Circulation.

[33]  G. Grassi,et al.  Sympathetic activation and loss of reflex sympathetic control in mild congestive heart failure. , 1995, Circulation.

[34]  D. Morgan,et al.  Sustained increases in aortic depressor nerve activity after acute elevation in arterial pressure , 1994, Journal of hypertension.

[35]  G A McPherson,et al.  Heart Rate Spectral Analysis, Cardiac Norepinephrine Spillover, and Muscle Sympathetic Nerve Activity During Human Sympathetic Nervous Activation and Failure , 1994, Circulation.

[36]  J. Heikkilä,et al.  Prevalence of aortic valve abnormalities in the elderly: an echocardiographic study of a random population sample. , 1993, Journal of the American College of Cardiology.

[37]  M. Mariani,et al.  [Spectrum analysis of heart rate variability in obstructive hypertrophic myocardiopathy. Evidence of altered autonomic function]. , 1992, Cardiologia.

[38]  A. Mark,et al.  Direct evidence from intraneural recordings for increased central sympathetic outflow in patients with heart failure. , 1986, Circulation.

[39]  P. Korner,et al.  Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity. , 1986, Circulation.

[40]  C. Indolfi,et al.  Pathophysiology of aortic stenosis and approach to treatment with percutaneous valve implantation. , 2011, Circulation journal : official journal of the Japanese Circulation Society.

[41]  J. Fajadet,et al.  Thirty-day outcome and vascular complications after transarterial aortic valve implantation using both Edwards Sapien and Medtronic CoreValve bioprostheses in a mixed population. , 2010, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[42]  M. Cheitlin.  United States Feasibility Study of Transcatheter Insertion of a Stented Aortic Valve by the Left Ventricular Apex , 2009 .

[43]  D. Paterson,et al.  Should we still use nitrovasodilators to test baroreflex sensitivity? , 2000, Journal of hypertension.

[44]  K J Osterziel,et al.  Sympathetic activation and loss of reflex sympathetic control in mild congestive heart failure. , 1996, Circulation.